

For Immediate Release

June 6, 2017

Update on USDA inspection at UQUIFA's facility in Spain

This is to inform that the company's API manufacturing facility located in Sant Celoni, Spain was recently inspected by the US FDA in compliance with their requirements. At the end of the successful inspection, we have been informed by the investigator that "zero" 483 observations were issued. This was a routine inspection by the US FDA.

Kindly take the above for your record.

About Vivimed Labs Limited:

Vivimed labs limited established in 1991, in Hyderabad, is a globally renowned supplier of niche molecules and formulations across Healthcare, Pharmaceuticals and Speciality Chemicals consumers in nearly 50 countries

Vivimed Labs has two business divisions:

Healthcare Division, which manufactures APIs and formulations covering diverse therapeutic segments and has a marketing presence across regulated and pharmerging markets

Specialty Chemicals division, they are a global leader in hair dyes, photochromic, and antimicrobials products

The Company has 11 manufacturing plants across India(8) and Overseas(3). Of the existing 11 plants, 4 plants are USFDA approved. The Company has 5 dedicated R&D centres (3 in India and 2 in Overseas). The Company's clientele base is strong in both its Healthcare and Specialty segments as it enjoys a leadership in API and hair dyes products.

For further information on Vivimed, visit www.vivimedlabs.com

Analyst and Investor Enquiries

Sunil Arab, VP Corporate Strategy
Vivimed Labs Limited

+91 40 2717 6005
sunil.arab@vivimedlabs.com

*Payal Dave, Group COO
Strategic Growth Advisors*

+91 22 6114 6679
payal.dave@sgapl.net

*Rahul Agarwal, Business Analyst
Strategic Growth Advisors*

+91 22 6114 6605
rahul.agarwal@sgapl.net

For VIVIMED LABS LTD.



Vivimed

Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For VIVIMED LABS LTD.


Managing Director